Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Caitriona McLean*, Catherine M Greene*, Noel G McElvaneyRespiratory Research Division, Dept. Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland; *Each of these authors contributed equally to this workAbstract: Alpha-1 antitrypsin (A1AT...
Guardado en:
Autores principales: | Caitriona McLean, Catherine M Greene, Noel G McElvaney |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/03de50986b7b4813ac5ce3b18ebd77f0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea DM, et al.
Publicado: (2018) -
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Irina Petrache, et al.
Publicado: (2009) -
Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens.
por: George Marek, et al.
Publicado: (2021) -
The role of TIM-containing molecules in airway disease and their potential as therapeutic targets
por: Vega-Carrascal I, et al.
Publicado: (2012) -
Correction to: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
por: Alexa Núñez, et al.
Publicado: (2021)